| Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. | |
| | |
MedLine Citation:
|
PMID: 17435415 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, and it shows favorable antitumor activity against chemorefractory nonsmall cell lung cancer (NSCLC). However, patients with NSCLC have few treatment options available if they are refractory to gefitinib. We describe a 49-year-old patient with NSCLC who had a complete response to initial gefitinib that lasted for 12 months. The tumor relapsed, and the patient received cytotoxic chemotherapy. However, despite chemotherapy, the patient had radiographic progression of lung metastases and we commenced retreatment with gefitinib, showing a remarkable effect. Epidermal growth factor receptor (EGFR) gene analysis showed deletion mutations in codon 745-750 in exon 19 and EGFR gene amplification. Our case shows that after retreatment with gefitinib, patients may show a remarkable response if they showed a remarkable response to initial gefitinib administration and if a certain time has elapsed since the previous gefitinib treatment. |
| | |
Authors:
|
Akihiro Yoshimoto; Kanako Inuzuka; Toshiyuki Kita; Atsuhiro Kawashima; Kazuo Kasahara |
Related Documents
:
|
16088755 - Evidence-based outcomes for patients with advanced non-small cell lung cancer. 17972525 - Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-st... 20199975 - Prognostic value of computed tomography morphologic characteristics in stage i non-smal... 8959675 - Second primary lung cancer in flanders: frequency, clinical presentation, treatment and... 9071335 - Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and ... 15208495 - Six month follow-up after 111in-dtpa-octreotide therapy in patients with progressive ra... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: The American journal of the medical sciences Volume: 333 ISSN: 0002-9629 ISO Abbreviation: Am. J. Med. Sci. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-04-16 Completed Date: 2007-05-17 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0370506 Medline TA: Am J Med Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 221-5 Citation Subset: AIM; IM |
Affiliation:
|
Department of Internal Medicine, Yokohama Kosei Hospital, Yokohama, Japan. yoshimoto@guitar.ocn.ne.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Base Sequence Carcinoma, Non-Small-Cell Lung / drug therapy*, genetics DNA, Neoplasm Gene Amplification Humans Lung Neoplasms / drug therapy*, genetics Male Middle Aged Mutation Quinazolines / therapeutic use* Receptor, Epidermal Growth Factor / genetics Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/DNA, Neoplasm; 0/Quinazolines; 184475-35-2/gefitinib; EC 2.7.10.1/Receptor, Epidermal Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A large abdominal wall mass as an initial manifestation of malignant mesothelioma.
Next Document: Reversible congestive heart failure related to profound hypocalcemia secondary to hypoparathyroidism...